Company Update – in Connection with the Annual General Meeting, June 10, 2021

Click below to read the presentation. Sobrera Update June 2021

Sobrera Pharma receives patent approval in Europe

Sobrera Pharma AB is pleased to announce the Decisions to Grant on the European patent 3582764 titled ’Treatment of Alcohol Use’ by the European Patent Office (EPO). The decision to grant on the [...]

Recruitment ongoing in the phase II study (COMB study).

Recruitment of patients to the phase II study (COMB study) is ongoing at the clinical study site in Gothenburg and in Stockholm. The study team is sharing information about the study including [...]

Sobrera Pharma AB announces 28 MSEK capital raise through a directed share issue to finance the continued development of SO-001

Sobrera Pharma AB announces 28 MSEK capital raise through a directed share issue to finance the continued development of SO-001, a new oral therapy for patients with Alcohol Use Disorder (AUD). [...]

Anders Milton är ny styrelsemedlem i Sobrera Pharma AB

Sobrera Pharma and Recipharm in collaboration to advance a new treatment for patients with Alcohol Use Disorder

Swedish life science company, Sobrera Pharma, and global contract development and manufacturing organisation (CDMO), Recipharm, have entered into an agreement for the formulation development and [...]

News

Combined administration of varenicline and bupropion produces additive effects on accumbal dopamine and abolishes the alcohol deprivation effect in rats

Combined administration of varenicline and bupropion produces additive effects on accumbal dopamine and abolishes the alcohol deprivation effect in rats Bo Söderpalm | Klara Danielsson | Andrea [...]

Project

Partners

page 1 of 2